Novavax (NVAX) Retained Earnings (2010 - 2026)
Novavax's (NVAX) quarterly Retained Earnings came in at $4.5 billion in Q1 2026, up 0.79% year-on-year from $4.5 billion in Q1 2025, and up 199.57% quarter-over-quarter from -$4.6 billion in Q4 2025.
Novavax (NVAX) Retained Earnings (2010 - 2026) Analysis & Trends
Novavax's Retained Earnings history runs 17 years deep, the most recent figure standing at $4.5 billion for Q1 2026.
- On a quarterly basis, Retained Earnings rose 0.79% year-over-year to $4.5 billion in Q1 2026; TTM through Mar 2026 was $4.5 billion, a 0.79% increase from a year earlier, with the FY2025 full-year figure at -$4.6 billion, up 8.79% from the prior year.
- Retained Earnings grew to $4.5 billion in Q1 2026 per NVAX's latest filing, from -$4.6 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $4.5 billion in Q1 2026 and bottomed at -$5.0 billion in Q4 2024.
- The 5-year median for Retained Earnings is $3.6 billion (2022), against an average of $802.7 million.
- Across the five-year window, Retained Earnings sank 371.32% in 2022 and surged 65838.81% in 2023, its largest moves.
- Year by year, Retained Earnings stood at -$6.4 million in 2022, then jumped by 65838.81% to $4.2 billion in 2023, then plunged by 219.47% to -$5.0 billion in 2024, then advanced by 8.79% to -$4.6 billion in 2025, then surged by 199.57% to $4.5 billion in 2026.
- Per Business Quant, the three latest NVAX Retained Earnings figures stand at $4.5 billion (Q1 2026), -$4.6 billion (Q4 2025), and -$4.6 billion (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | 4.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.55 Bn |
| Dec 31, 2025 | -4.57 Bn |
| Sep 30, 2025 | -4.59 Bn |
| Jun 30, 2025 | 4.52 Bn |
| Mar 31, 2025 | 4.51 Bn |
| Dec 31, 2024 | -5.01 Bn |
| Sep 30, 2024 | -4.93 Bn |
| Jun 30, 2024 | 4.48 Bn |
| Mar 31, 2024 | -10.83 Mn |
| Dec 31, 2023 | 4.19 Bn |
| Sep 30, 2023 | 4.07 Bn |
| Jun 30, 2023 | 3.86 Bn |
| Mar 31, 2023 | -4.57 Bn |
| Dec 31, 2022 | -6.38 Mn |
| Sep 30, 2022 | -23.79 Mn |
| Jun 30, 2022 | 3.60 Bn |
| Mar 31, 2022 | 3.57 Bn |
| Dec 31, 2021 | -1.35 Mn |
| Sep 30, 2021 | 3.31 Bn |
| Jun 30, 2021 | 3.24 Bn |